Overview

Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)

Status:
Completed

Trial end date:
2020-08-28

Target enrollment:

Participant gender:

Summary

The primary objective of this study was to evaluate the safety, as assessed by incidence of dose limiting toxicity (DLT), of talimogene laherparepvec in combination with pembrolizumab in adults with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Phase:

Phase 1

Details

Lead Sponsor:

Amgen

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab
Talimogene laherparepvec